Vivtex to apply its GI-ORIS™ technology to optimize oral bioavailability of EQ302, Equillium’s novel IL-15/IL-21 bi-specific peptide therap...
Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion coho...
China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal...
VS-041, a novel and potentially life-saving treatment for heart failure, developed by Vasa Therapeutics, a San Diego-based biotechnology comp...
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivot...
Symbiosis Pharmaceutical Services Ltd (Symbiosis), a rapidly growing sterile biopharmaceutical Contract Manufacturing Organisation (CMO) announces the pu...
PTG-007 cell therapy resulted in clinical remission in some patients for up to 12 years A proportion of patients remained insulin-independent for up t...
Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Resear...
Moderna, Inc. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion r...
Orphan designation shows recognition of therapeutic potential of drug candidate SBL01 targeting two regulated cell death pathways European Medicines A...
Phase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C r...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd , announced that the Company has sign...
PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s partner, LMI This Fast Track designation applies across Al...
LIXTE Biotechnology Holdings, Inc. announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer In...
© 2025 Biopharma Boardroom. All Rights Reserved.
